COST PER RECURRENCE-FREE SURVIVOR (CPRS) AND COST PER RECURRENCE-FREE LIFE MONTH (CPRLM) OF ADJUVANT NIVOLUMAB (NIVO) VERSUS PEMBROLIZUMAB (PEMBRO) AMONG PATIENTS WITH RESECTED STAGE IIB/IIC MELANOMA

被引：0
|
作者：
Davis, J. M. [1 ]
Srinivasan, S. [2 ]
Du, E. X. [3 ]
Xu, C. [3 ]
Linton, J. [2 ,3 ]
Betts, K. [3 ]
Shelley, K. [2 ]
机构：
[1] Atrium Hlth Levine Canc, Charlotte, NC USA
[2] Bristol Myers Squibb, Lawrenceville, NJ USA
[3] Anal Grp Inc, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE47
引用
收藏
页码：S65 / S65
页数：1
相关论文
共 10 条
  • [1] Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma
    Samlowski, Wolfram
    Silver, Michelle A.
    Hohlbauch, Andriana
    Zhang, Shujing
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    Wang, Yunfei
    Sruti, Ila
    Jiang, Ruixuan
    MELANOMA RESEARCH, 2024, 34 (04) : 326 - 334
  • [2] Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
    Weber, J.
    Del Vecchio, M.
    Mandala, M.
    Gogas, H.
    Arance Fernandez, A. M.
    Dalle, S.
    Cowey, C. L.
    Schenker, M.
    Grob, J-J.
    Sileni, V. Chiarion
    Marquez-Rodas, I.
    Butler, M. O.
    Maio, M.
    Middleton, M.
    de la Cruz Merino, L.
    Lobo, M.
    de Pril, V.
    Larkin, J.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S731 - S732
  • [3] Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry
    Ozkan, A.
    Kapiteijn, E.
    van den Bos, F.
    Aarts, M. J. B.
    van den Berkmortel, F. W. P. J.
    Blank, C. U.
    Bloem, M.
    Blokx, W. A. M.
    Boers-Sonderen, M. J.
    Bonenkamp, J. J.
    van den Eertwegh, A. J. M.
    de Groot, J. W. B.
    Haanen, J. B.
    Holtslag, C. E.
    Hospers, G. A. P.
    Piersma, D.
    van Rijn, R. S.
    Boer, A. M. Stevense-den
    Suijkerbuijk, K. P. M.
    van der Veldt, A. A. M.
    Vreugdenhil, G.
    Wouters, M. W. J. M.
    Portielje, J. E. A.
    de Glas, N. A.
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [4] 3-Year Results Adjuvant Nivolumab Therapy continues to show longer recurrence-free Survival in High-risk Patients with resected Melanoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (12) : 703 - 703
  • [5] Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
    Jeffrey S. Weber
    Tayla Poretta
    Brian D. Stwalley
    Leon A. Sakkal
    Ella X. Du
    Travis Wang
    Yan Chen
    Yan Wang
    Keith A. Betts
    Alexander N. Shoushtari
    Cancer Immunology, Immunotherapy, 2023, 72 : 945 - 954
  • [6] Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
    Weber, Jeffrey S.
    Poretta, Tayla
    Stwalley, Brian D.
    Sakkal, Leon A.
    Du, Ella X.
    Wang, Travis
    Chen, Yan
    Wang, Yan
    Betts, Keith A.
    Shoushtari, Alexander N.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (04) : 945 - 954
  • [7] Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAFV600-Mutant Stage III Melanoma Seems to be Short-Lived
    Hess, Kenneth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15) : 1354 - +
  • [8] " Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056]
    Ozkan, A.
    Kapiteijn, E.
    van den Bos, F.
    Aarts, M. J. B.
    van den Berkmortel, F. W. P. J.
    Blank, C. U.
    Bloem, M.
    Blokx, W. A. M.
    Boers-Sonderen, M. J.
    Bonenkamp, J. J.
    van den Eertwegh, A. J. M.
    de Groot, J. W. B.
    Haanen, J. B.
    Holtslag, C. E.
    Hospers, G. A. P.
    Piersma, D.
    van Rijn, R. S.
    Stevense-den Boer, A. M.
    Suijkerbuijk, K. P. M.
    van der Veldt, A. A. M.
    Vreugdenhil, G.
    Wouters, M. W. J. M.
    Portielje, J. E. A.
    de Glas, N. A.
    EUROPEAN JOURNAL OF CANCER, 2025, 216
  • [9] Phase III KEYNOTE-716 Study of Pembrolizumab (KEYTRUDA®) as adjuvant Therapy for Patients with resected Stage IIB or IIC Melanoma: significant Improvement in distant metastasis-free Survival versus Placebo
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [10] Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial
    Eggermont, Alexander M. M.
    Kicinski, Michal
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina V.
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Di Giacomo, Anna Maria
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul C.
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    van Akkooi, Alexander
    Robert, Caroline
    Suciu, Stefan
    JAMA ONCOLOGY, 2020, 6 (04) : 519 - 527
1